Already a DIA Member? Sign in. Not a member? Join.

Iniciar sesión

¿Ha olvidado su ID de usuario? or ¿Ha olvidado su contraseña?

Not a Member?

Create Account and Join

Hotel Grand Majestic Plaza

15 jun 2017 8:15 a.m. - 16 jun 2017 5:00 p.m.

Truhlarska 16, 110 00 Prague 1, Czech Republic

DIA Workshop on Benefit-Risk Strategy

Session 6: PRAC Referrals – Lessons Learned

Session Chair(s)

Martin  Huber, MPH, MPharm

Martin Huber, MPH, MPharm

Pharmacovigilance Risk Assessment Committee (PRAC) Vice Chair, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Martin  Votava, MD, PhD

Martin Votava, MD, PhD

Chief Medical Officer , PrimeVigilance, Czech Republic

Pharmacovigilance referrals are important tools to address concerns over the safety profile or the benefit-risk balance of a medicine or a class of medicines. This session will look into finished referrals but will also reflect on future challenges both from a regulator’s and industry perspective. The following aspects will be discussed: - Describing the evolution of referrals including recent trends - Reflecting on what can be learnt from experience gathered so far - Looking into future challenges – what can be improved?

Speaker(s)

Álmath  Spooner, PhD

Álmath Spooner, PhD

Director of Regulatory Policy and Intelligence, AbbVie, Ireland

Referrals at PRAC – Recent Trends and Future Challenges

Vera  Tóth, MD

Vera Tóth, MD

Medical Expert, Gedeon Richter Plc., Hungary

Implementing CHMP/PRAC Conditions: Pitfalls and Challenges

¿Tiene una cuenta?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.